

EDITORIAL

by *Lina Badimon, President of ESCI*

FROM THE PRESIDENT

Here, again and for the last time, I am introducing the ESCI Newsletter. Indeed, this is going to be my last Editorial as President of our Society. I am sad to be giving up the presidency because it has been one of the most gratifying activities I have performed over the last years. However, I believe that at the present time we have a strong Society with a hard-working and committed Council. I also have great expectations on the next President, on his leadership and drive to take our Society into the next three years. The Council has unanimously proposed Heinrich Schulte, known to all of you because of his dedication to ESCI in other Council positions in the past, as the next President and he will be presented to you at the Annual Business Meeting in Brussels.

I had the honor to be the local organizer of the 35th Annual Meeting of ESCI held in Barcelona. We had a good meeting with participants not only from Europe but from America and Asia (Japan) as well. It was a lot of work because it was a joint meeting with the Spanish Society of Atherosclerosis. However, the integration of scientists and clinicians at a National and European level was worth the effort. This year we will meet in Brussels under the organizational skills of Patrick Evrard and his team and in 2003 we will gather in Italy guided by Giovanni Ricevuti, Councillor and future Vice-President of ESCI, who is already organizing the meeting.

As announced in my last newsletter our website is working (www.esci.eu.com) and we have used it to submit the abstracts to the ESCI-2002 meeting. Please visit the web and send any suggestions to the Central Office in Utrecht (Jos Sperna Weiland).

The new elected members of the Council Bruno Fouqueray (France) and Marek Sanak (Poland), elected in the year 2001, were cordially welcomed and are already actively working for ESCI. We have to give our farewell to Peter Ott (Denmark) who has served the Society with enthusiasm for the last years, Martin Reincke (Germany) who had to unexpectedly leave the Council because of personal reasons and Michael Roden (Austria). Michael was our Honorary Secretary-Treasurer and he is going to be a Board member of the ESDA. We thank them for all their work and dedication to ESCI.

One of the identity markers of ESCI is our journal, The European Journal for Clinical Investigation. The leadership of Jo Marx, Editor-in-Chief of EJCI, in driving the journal

in the last years has been generally acknowledged. Jo Marx has been the Editor-in-Chief during my tenure as President and I am most grateful to him for his magnificent work, his attitude and good will. The good work of Jos Sperna Weiland, EJCI secretary, is also dearly acknowledged.

I will miss, on leaving the presidency, the contact with the Council of ESCI. I have made great friends while at the Council, persons of different backgrounds with similar interest for improving science, medicine and communication between scientists in Europe. The future awaits and I predict that the renewed Council of ESCI with its new President will be ready to meet its challenges with the knowledge of the past and a strong faith in European Science.

ANNOUNCEMENT

37th Annual Scientific Meeting of the European Society for Clinical Investigation

"The Pathophysiology of Diseases: from bench to bedside"
Verona, Italy, April 2003



by *Giovanni Ricevuti, local organizer*

Dear Colleague,
Welcome to Italy, the "country of Saints, Poets, Artists, Heroes, Sailors....and scientists as well". We invite you to join us to the 37th Annual Scientific Meeting of the European Society for Clinical Investigation that will be held in Verona, April 2003. Verona, inextricably linked to Romeo and Juliet, is a very old historical city situated in the north of Italy, close



to Venice, in the hearth of Europe. It is full of historical buildings, including the world famous "Arena di Verona", with its equally famous opera season.

This congress will stress "**The Pathophysiology of Diseases: from bench to bedside**" and would like to act as a service for all interested scientists to discuss specific topics at a very high level. At the beginning of the new millennium we invite you to collaborate with us in the success of an exciting and productive meeting with topics ranging from basic to clinical research. This meeting will allow you to acquire information and inputs relevant to your daily medical practice and research. The meeting will offer several plenary sessions, main and keynote lectures, symposia, workshops, debate sessions, "meet the expert" sessions, free oral communication, poster sessions, and joint symposiums with other societies.

Enjoy the interesting topics discussed, enjoy history, art and music too. Strengthen old friendships and make new ones and above all enjoy the beauty of Italy!

I hope to see you in Verona.

■ AREAS OF INTEREST

- Biochemistry
- Cardiology
- Clinical Chemistry
- Clinical Pathophysiology
- Clinical Trials
- Emergency Medicine and Critical Care
- Endocrinology/Diabetology
- Gastroenterology/Liver
- Haematology/Oncology
- Immunology and Inflammation
- Infectious Diseases
- Internal Medicine
- Lipid Metabolism
- Methodology in Research
- Methods in Cellular Analysis
- Methods in Immunology
- Molecular Pathophysiology
- Nephrology/Hypertension
- Neurology
- Nutrition
- Occupational Medicine
- Periodontology
- Pharmacology
- Respiratory Medicine
- Rheumatology
- Thrombosis and Haemostasis
- Therapeutic Protocols
- Toxicology

INFORMATION AND REQUESTS

Giovanni Ricevuti, MD
Department of Internal Medicine and Therapeutics
University of Pavia – IRCCS Policlinico san Matteo
P.1e Golgi 2
I-27100 Pavia
Italy
Phone +39 0382 502499
+39 0382 526944
Fax +39 0382 526950
E-mail g.ricevuti@smatteo.pv.it
giovanni.ricevuti@unipv.it

THE ESCI AWARD FOR EXCELLENCE IN CLINICAL SCIENCE 2001

by J.J.M. Marx

The ESCI Award for Excellence in Clinical Science for the year 2001 was given to Professor **Hans C Clevers** from the University of Utrecht, The Netherlands. Hans Clevers was born in 1957, completed two academic educations (Biology and Medicine), and received a PhD degree (Immunology) in 1985, all at the University of Utrecht. From 1985-1989 he was a postdoctoral fellow in Pathology at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA, working with Cox Terhorst. In 1989 he came back to Utrecht and in 1991, at the age of 34, he was appointed to be full professor and head of the Department of Clinical Immunology at the University Medical Centre Utrecht. Within a few years he succeeded to make this department to be one of the leading centres of immunology in the world with breathtaking research in the fields of Immunology and Developmental Biology.



Hans Clevers received the ESCI award on May 3, 2001 during the Annual Scientific Meeting of ESCI in Barcelona. Left: Prof. Lina Badimon, President of ESCI, right: Prof. Hans Clevers.

Hans Clevers studies control of mammalian development at the level of transcription. Initially focussing on lymphocyte differentiation models he contributed, during his Boston period, considerably to the understanding of the transcriptional control of the CD3- ϵ gene. Back in Utrecht, he searched for transcription factors that were lymphoid-restricted. He was able to clone a novel gene and designated this Tcf-1 (T cell factor 1), followed by the cloning of a close relative, called Sox-4, both members of the HMG-box family of transcription factors that change the topology of DNA. He demonstrated that Tcf is involved in T cell development, and that Sox-4, a close relative of the mammalian sex-determining gene Sry, controls cardiac development as well as the development of B lymphocytes. He was responsible for molecular definition of most currently known Tcf/Lef family members. The in vivo importance of several of these genes was demonstrated using *Xenopus*, *Drosophila* and *C. elegans*, leading to the seminal finding that factors of the Tcf family constitute the ultimate effectors of the Wntless/Wnt cascade. Clevers found that Tcf proteins are partners of β -Catenin (a homolog of Armadillo in *Drosophila*), a key component of cell-cell adhesive junctions. He discovered that Wnt signalling is essential for many developmental events, and that the Tcf/ β -Catenin complex activates transcription, rather than Tcf itself. These results had important implications for understanding the aetiology of colon cancer. Like mutations in the APC (Adenomatous polyposis coli) gene, β -catenin mutations lead to familial predisposition to colon cancer. Under normal circumstances the APC gene product, together with axin/GSK-3, binds β -catenin and keeps its levels under control. Clevers showed that the gut-specific transcription factor Tcf-4 formed a stable complex with free β -catenin, present at excessive levels in APC-defective cells, leading to activation and expression of target genes leading to cell proliferation. This demonstrated that the protein products of mutant APC genes present in colorectal neoplasia are defective in down regulating transcriptional activation mediated by β -catenin and Tcf. Thus, β -catenin and Tcf were firmly established as accomplices in causing cancer of the colon and many other organs. Blocking Tcf activity in colon cancer cell lines causes an immediate cell cycle arrest and induces differentiation.

The findings of Hans Clevers open possibilities for an exciting, new strategy for the development of anti-cancer drugs. Hans Clevers has the typical profile of an ESCI award laureate, bridging the gap between molecular and medical science, employing novel technologies and model organisms. His scientific excellence brought him already many honours and awards, most recently the prestigious Spinoza prize. The quality of his work can be easily recognized from his superb scientific production, including 29 papers in *Cell*, *Nature*, *Science*, *PNAS*, *Journal of Experimental Medicine*, *Journal of Clinical Investigation*, and *New England Journal of Medicine*. In 2000 he was appointed to be a Member of the Royal Dutch Academy of Sciences (KNAW). Since 1996 Hans Clevers is an associate editor of the *European Journal of Clinical Investigation*.

NEW COUNCILLORS 2002

The Council would like to propose Olivier Gurné and Giovanni Ricevuti for Vice-Presidency.

Moreover, for the office of President the Council proposes Heinrich Schulte and for the office of Secretary-Treasurer Robin Dullaart is proposed. Hereunder you will find the summarised curricula vitae of the candidates proposed for the office of President and of Secretary-Treasurer.

The curricula vitae of the candidates nominated for councillorship are listed as well. The resigning councillor in 2002 is Peter Ott from Denmark. You will also find candidates for Spain and Austria. As usual you can choose between the two candidates per country on the enclosed ballot paper. The ballot paper should be returned immediately to the Central Office of ESCI. Exact instruction can be found on the ballot paper. A simple majority vote is decisive in each case.

Proposal President

Prof. Dr. Heinrich M Schulte (MD) is a co-founder and primary investor of EVOTEC BioSystems AG. He has been on the Company's Board since 1994 and became a member of the Scientific Advisory Board in 1998. Dr. Schulte has been Director of the Institute for Hormone and Fertility Research at the university of Hamburg from 1993 to 1998. He is Professor of Medicine and Endocrinology (Christian-Albrechts-University, Kiel from 1986 through 1993, and University of Hamburg since then). Heinrich Schulte conducted research at the National Institutes of Health's Developmental Endocrinology Branch in Bethesda, Maryland, USA, from 1981 through 1983, and the NIH's Neurology Branch from 1989 to 1990. He held a guest-professorship at the Faculty of Medicine, University of Hangzhou, China, in 1990.



Dr. Schulte is an ESCI member for many years. He was a councillor from 1993-1996, vice-president 1996-1997, and secretary-treasurer from 1997-2000.

Proposal Secretary-Treasurer

Robin P F Dullaart is 45 years old and graduated in medicine at the University of Utrecht, The Netherlands, in 1981. After his residency in internal medicine he became Associate Professor of Endocrinology at the University of Groningen, The Netherlands. In 1990 he completed his PhD thesis (lipid metabolism) at the University of Utrecht on cholesterylester transfer protein. His main research activities are focused on secondary forms of hyperlipidaemia, lipid transfer proteins and treatment of diabetic nephropathy. He is (co-)author of about 100 papers and a similar number of abstracts. Robin Dullaart is an ESCI councillor since 1998.



Council candidates Spain

Pedro Mata is 54 years old. He is associated chief of the Internal Medicine Department and of the Lipid Clinic at Fundación Jiménez Díaz, Madrid. He graduated in 1977 at the Medical School of Universidad Autónoma de Madrid. He was a visiting scientist in the lipid laboratory at USDA, Human Nutrition Research Center in Aging, Tufts University, Boston. He is the President and Medical Director of the Spanish Familial Hypercholesterolemia Foundation. His major research includes lipoprotein metabolism, management of cardiovascular risk factors, with special stress on the effects of dietary fatty acids on lipoproteins and in several mechanisms related to the pathogenesis of atherosclerosis in humans, and the interaction between diet and genetics. Another field of his research is familial hypercholesterolemia, especially genetic aspects, its interaction with other risk factors and new focus in treatment.

Dr. Mata is the author of over 50 scientific articles, and textbook chapters, and lecturer on lipoproteins, hyperlipidemia, diet and cardiovascular disease.

Juan L Tamargo, Professor of Pharmacology, Universidad Complutense Madrid, is 53 years old and graduated in Medicine from the Valladolid University Medical School in 1970. He was trained in pharmacology and got his PhD in 1973. He is a European Hypertension Specialist of the European Society of Hypertension (2001). He has spent research time in the State University of New York Upstate Medical Center, Syracuse, NY (1993-1995), in the Physiology Institute of the University of Saarland, Germany (1976-1980, 4 months/year), and in the Department of Physiology, SUNY/Downstate Science Center (1986-1989, 4 months/year).

During his career he has received many awards and honours and he is a Fellow of the European Society of Cardiology, American Heart Association, World Academy of Art and Science and Member of the Spanish Royal Academy of Pharmacy. He is member of the Editorial Board of different journals in the area of cardiac electrophysiology and cardiovascular pharmacology, which are his main research interests. He has published more than 165 papers in SCI journals, over 131 book chapters and 22 monographs. In addition, he has published many papers in national journals. He was the President of the Spanish Society of Pharmacology (1994-1997) and he is Member of the Advisory Board of the European Society of Pharmacology (1994-).

the Spanish Royal Academy of Pharmacy. He is member of the Editorial Board of different journals in the area of cardiac electrophysiology and cardiovascular pharmacology, which are his main research interests. He has published more than 165 papers in SCI journals, over 131 book chapters and 22 monographs. In addition, he has published many papers in national journals. He was the President of the Spanish Society of Pharmacology (1994-1997) and he is Member of the Advisory Board of the European Society of Pharmacology (1994-).

Council candidates Denmark

Henning Grønbaek is 38 years old. He graduated from Aarhus University in 1991. He has had a number of clinical training positions, since 1995 at the University Hospital of Aarhus, including the Department of Endocrinology, Haematology, Infectious Diseases, Gastroenterology and



Hepatology. He is currently a senior registrar at the Department of Gastroenterology and Hepatology. His clinical focus has been on the internal medical specialities: endocrinology, nephrology and hepatology. At the age of 27 he finished his master of medical science thesis dealing with selenium metabolism in the anterior pituitary gland of selenium intoxicated rats. After three years as a scientific fellow from 1992 to 1995 at the

Medical Research Laboratory, Aarhus University Hospital, he prepared his PhD thesis on the effects of growth factors and growth factor inhibitors on the development of diabetic nephropathy in experimental diabetes in rats. He is the author or co-author of 40 original papers and 19 reviews in peer-reviewed journals. These papers mainly deal with the effects of growth hormone and receptors in diabetes and its relation to complications including renal disease. Recently he has expanded his field of interest to also cover the effects of growth factors in liver disease, as well as the relationship between insulin resistance and non alcoholic steatosis. His scientific strength is to work at the interface between basic laboratory and clinical research. Thus his papers include basic molecular biological studies in animal models as well as clinical studies in patients. He is currently the supervisor for a Danish PhD student and a Belgian student under the ERASMUS research program.

He has participated in establishing the Society for PhD Students at the Faculty of Health Science, Aarhus University, and was a member of its Committee 1995-1996. As part of this he conducted an in depth examination of the working conditions of 171 PhD students in Aarhus. He is a member of the Danish Medical Association, The Danish Endocrine Society, the Danish Association for the Study of the Liver, and the Danish Society of Gastroenterology.

Kim Dalhoff is 44 years old. He graduated as a medical doctor from the University of Copenhagen in 1983. His clinical training concentrated on internal medicine and hepatology and in 1997 he specialized in hepatology. During



a three years period as a research fellow at the Department of Hepatology at Copenhagen University Hospital, he studied the regulation of sulphation and glutathione conjugation of drugs in isolated rat hepatocytes. In 1996 he became Doctor of Medical Science with a thesis based on his publications within this field. In his further research he has extended this interest to a broad range of aspects of clinical pharmacology and including

epidemiological, immunological, toxicological and transplantation topics. He has published 46 papers in peer reviewed journals. His interest in the clinical aspects of pharmacology led him to his current position as a Senior Consultant at the Department of Clinical Pharmacology at Copenhagen University Hospital. Along with his continued clinical research he is active as a longstanding member

of The Drug Administration Committee for Copenhagen University Hospital, for which he is now the Chairman and as a Secretary for the Pharmacological Department of the Danish National Board of Health. He is a member of the Danish Society for the Study of the Liver of which he was a Board member 1996-2000. At present, he is a member of the Board of the Danish Association for Clinical Pharmacology, and of the Council of the European Association for Clinical Pharmacology and Therapeutics. He took part in organizing the 5th Congress of the European Association for Clinical Pharmacology and Therapeutics, Odense 2001, as a member of the National Advisory Board.

Council Candidates Austria

Wolfgang Graier, born March 4, 1963 in Graz, Austria, married and two sons. After finishing his study on Pharmaceutical Chemistry and Pharmacy 1998 (MS), at the University of Graz, he made his PhD in Pharmacology on the importance of Ca^{2+} concentration on nitric oxide synthase in endothelial cells at the Department of Pharmacology and Toxicology at the University of Graz (Chair W Kukovetz), Austria, where he graduated in 1992. After a Postdoc at the same department, he spent 1993 to 1994 at the Dalton Cardiovascular Research Center, University Columbia, Missouri, USA, where he learned electrophysiology and human physiology. In 1994 he returned to Graz as an Assistant Professor at the



Department of Medical Biochemistry and Medical Molecular Biology (Chair GM Kostner), made his habilitation in *Biochemical Pharmacology* 1995 and was promoted to an Associate Professor 1998. Early 2001, he made an additional habilitation in *Physiology*.

As the group leader of the Vascular Cell Biology Laboratory he has published about 63 original papers summing up to approximately 210 impact points so far and was honored 14 times by national and international awards. As a member of the American Diabetes Association, the American Heart Association, the American Physiological Society, the Swiss Society for Pharmacology and Toxicology, the British Pharmacological Society and the British Physiological Society he is involved in several reviewing panels. Moreover, since 2000 he is Associate Editor for *Diabetologia* and Editor of *The British Journal of Pharmacology* and elected to the editorial board of *The Journal of Cardiovascular Pharmacology* from 2002.

His main research interests are focused on endothelial cell function and dysfunction in diabetes, hypercholesterolemia and hypertension. The laboratory techniques are designed to investigate endothelial cell biology on the level of molecules, (single) cells up to intact blood vessels. His research activities also include a strong collaboration with partners at the University clinics. It is his strong believe that we have to bridge basic medical sciences with clinical science in order to perform good medical research in the future. Thus, wherever he may have the chance he will try to strengthen efforts for a better collaboration of basic medical sciences and clinical research.

Michael Wolzt, MD, born on July 5, 1967, in Vienna, Austria, He graduated from Vienna University and received his MD in 1991. He is Associate Professor of Internal Medicine (since 1999) and currently consultant at the Vienna General Hospital. His career spans specialist training in internal medicine and cardiology at the Vienna General Hospital, and post-graduate training at the Cruciform Project / University College London with P. Vallance and S. Moncada. He is head of the section of Cardiovascular Medicine at the Department of Clinical Pharmacology, member of the Medical Faculty, and the local Ethics Committee.



The scientific interest covers different clinical aspects of vascular function, and more than 70 original articles in peer-reviewed journals have been published.

36TH ANNUAL SCIENTIFIC MEETING OF ESCI

Brussels, Belgium, 10 – 13 April 2002

by Patrick Evrard, president local organizing committee

Welcome to Brussels!

As President of the Local Organizing Committee of the 36th ESCI meeting, I would like to welcome you to Brussels. The date of our Congress is approaching. The prospects of the meeting are excellent. Thanks to the diversity of topics in the workshops, the experience of the invited speakers and the continuing medical education offered by the 3rd Course on Molecular Biology, we hope to incite you to join us in Brussels. Moreover, the renown of exciting city life in Brussels ought no more to be done!

Welcome to Belgium!

SUMMARY (PRELIMINARY) SCIENTIFIC PROGRAMME

■ Wednesday 10 April 2002

14.00 - 18.00

Third Postgraduate Course on molecular biology: functional genomics

organised by *B Fouqueray*

It will include five lectures pertaining to functional genomics and give new insights in this rapidly moving field.

- Pharmacogenomics, pharmacogenetics: new concepts
E Thervet, Hospital Saint-Louis, Paris, France
- Diagnostic strategy of monogenic diseases
L Heidet, INSERM U423, Hospital Necker - enfants maladies, Paris, France
- Analysis of polymorphisms: the SNPs strategy
C Bétard, Centre National de Génotypage, Evry, France
- Identification of mutated genes after laser microdissection
A Vincent-Salomon, Institute Curie, Paris, France

- From gene to function: conditional knock-out
M Dewerchin, Belgium

15.00 - 19.00 **Registration**

19.00 - 21.00 **Welcome Cocktail**

■ Thursday 11 April 2002

8.30 - 8.45 **Opening Ceremony**

8.45 - 9.30 **Plenary Lecture**

'Generation of reactive oxygen species: a matter of life or death'

D Roos (Amsterdam, The Netherlands)

9.45 - 12.30 **Workshops**

10.45 - 11.15 Coffee break and poster viewing

02 Clinical and genetic aspects of postprandial lipemia

M Castro Cabezas (Utrecht, The Netherlands), J Ribalta (Reus, Spain)

03 Corticosteroid-induced osteoporosis, from cell to prevention

Y Boutsen (Yvoir, Belgium)

05 Hemodynamics and the cardiovascular risks

D Hayoz (Lausanne, Switzerland)

08 HDL function, reverse cholesterol transport and lipid transfer

RPF Dullaart (Groningen, The Netherlands), A van Tol (Rotterdam, The Netherlands)

10 Phagocytes: molecular basis of cell function
P Hordijk (Amsterdam, The Netherlands), L Dekker (London, UK)

13 Beyond statins for the control of hypercholesterolemia and cardiovascular disease

L Badimon (Barcelona, Spain)

20 The human maternal-fetal interface: from molecular biology to clinics

AM Bamberger, Th Löning, HM Schulte (Hamburg, Germany),

A Makrigiannakis (Heraklion, Greece)

12.30 - 14.00 **Lunch / poster viewing / exhibitions**

14.00 - 14.45 **Plenary Lecture**

'Therapeutic vaccination of melanoma patients'

Th Boon (Brussels, Belgium)

15.00 - 17.00 **Workshops**

02 Clinical and genetic aspects of postprandial lipemia

M Castro Cabezas (Utrecht, The Netherlands), J Ribalta (Reus, Spain)

03 Corticosteroid-induced osteoporosis, from cell to prevention

Y Boutsen (Yvoir, Belgium)

06 Endothelium in coronary disease

O Gurné, JL Balligant (Brussels, Belgium)

08 HDL function, reverse cholesterol transport and lipid transfer

RPF Dullaart (Groningen, The Netherlands), A van Tol (Rotterdam, The Netherlands)

10 Phagocytes: molecular basis of cell function
P Hordijk (Amsterdam, The Netherlands), L Dekker (London, UK)

13 Beyond statins for the control of hypercholesterolemia and cardiovascular disease

L Badimon (Barcelona, Spain)

20 The human maternal-fetal interface: from molecular biology to clinics

AM Bamberger, Th Löning, HM Schulte (Hamburg, Germany),

A Makrigiannakis (Heraklion, Greece)

17.00 - 18.30 **Satellite Symposium**

Osteoporosis: a call to action

■ Friday 12 April 2002

8.30 - 9.15 **Plenary Lecture**

'Recent advances in assessing cardiovascular neural regulation in health and disease'

A Malliani (Milano, Italy)

9.30 - 12.30 **Workshops**

10.45 - 11.15 Coffee break and poster viewing

06 Endothelium in coronary disease

O Gurné, JL Balligant (Brussels, Belgium)

09 Immunopharmacology of life-threatening diseases: insight into the new millennium

K Masek (Prague, Czech Republic), JW Hadden (USA)

10 Phagocytes: molecular basis of cell function
P Hordijk (Amsterdam, The Netherlands), L Dekker (London, UK)

11 Pain relief: from pathophysiology to therapeutic options

M De Kock (Brussels, Belgium)

12 Pediatric liver transplantation

E Sokal, J Lerut (Brussels, Belgium)

15 Primary pulmonary hypertension

M Leeman (Brussels, Belgium)

16 Prevention of restenosis after coronary angioplasty

E Schröder (Yvoir, Belgium), C Hanet (Brussels, Belgium)

12.30 - 14.00 **Lunch / poster viewing / exhibitions**

14.00 - 14.45 **Plenary Lecture ESCI Award 2002**

15.00 - 17.30 Poster viewing subspeciality sessions –
Chaired poster discussion - General oral session of selected posters

followed by **Poster Awards 2002**

■ Saturday 13 April 2002

8.30 - 9.15 **Plenary Lecture**

'The Nox family of NADPH oxidases'

JD Lambeth (Atlanta, USA)

9.30 - 12.30 **Workshops**

10.45 - 11.15 Coffee break and poster viewing

01 Gene polymorphisms in drug therapy

W Kirch, UI Schwarz (Dresden, Germany)

- 02 Clinical and genetic aspects of postprandial lipemia
M Castro Cabezas (Utrecht, The Netherlands), J Ribalta (Reus, Spain)
- 04 Microcirculatory abnormalities in sepsis and other inflammatory states
JL Vincent (Brussels, Belgium)
- 07 Iron in infection and inflammation
JJM Marx (Utrecht, The Netherlands), RR Crichton (Louvain-la-Neuve, Belgium)
- 10 Phagocytes: molecular basis of cell function
P Hordijk (Amsterdam, The Netherlands), L Dekker (London, UK)
- 14 Metabolic and neurohumoral parameters as risk factors in heart diseases
P Selvais (Maulde, Belgium), M Rousseau, M Hermans (Brussels, Belgium)
- 17 From nicotine receptor to smoking cessation
L Galanti (Yvoir, Belgium)

12.30 - 14.00 **Lunch / poster viewing / exhibitions**

14.00 - 17.00 **Workshops**

- 15.15 – 15.45 Coffee break and poster viewing
- 01 Gene polymorphisms in drug therapy
W Kirch, UI Schwarz (Dresden, Germany)
- 02 Clinical and genetic aspects of postprandial lipemia
M Castro Cabezas (Utrecht, The Netherlands), J Ribalta (Reus, Spain)
- 07 Iron in infection and inflammation
JJM Marx (Utrecht, The Netherlands), RR Crichton (Louvain-la-Neuve, Belgium)
- 10 Phagocytes: molecular basis of cell function
P Hordijk (Amsterdam, The Netherlands), L Dekker (London, UK)
- 18 Therapeutic options of monoclonal antibodies
A Bosly (Yvoir, Belgium)
- 19 Atrial fibrillation; new therapeutic options
L De Roy (Yvoir, Belgium), S Levy (Marseille, France), L Jordaens (Gent, Belgium)

■ **Important addresses**

Congress venue
Catholic University of Louvain
Faculty of Medicine – Main auditoria
Avenue E. Mounier 52
B-1200 Brussels
Belgium

Local organizer
Patrick Evrard
Catholic University of Louvain
ICU Department
Mont-Godinne University Hospital
B-5530 Yvoir
Belgium
phone +32 81 423021
fax +32 81 423023
e-mail docmed@mont.ucl.ac.be

Congress office
Travex Congrès
Parvis de la Trinité 8
B-1050 Brussels
Belgium
phone +32 2 533 2044/45
fax +32 2 537 7588
e-mail b.vandermeuse@travex-codetem.be

All information about the 36th Annual Scientific Meeting can be found on the ESCI website:
<http://www.esci.eu.com/>

FUTURE ANNUAL SCIENTIFIC MEETINGS

2002, 10 – 13 April

Brussels, Belgium
Local organizer: Patrick Evrard
(see editorial and preliminary programme in this Newsletter)

2003, April

Verona, Italy
Local organizer: Giovanni Ricevuti
(see announcement in this Newsletter)

2004, Spring

Utrecht, The Netherlands
Local organizer: Joannes Marx

ADDRESS CENTRAL OFFICE ESCI

Central Office European Society for
Clinical Investigation (ESCI)
Ms Jos Sperna Weiland
Bolognalaan 34
3584 CJ Utrecht
The Netherlands
phone +31 30 2508787
fax +31 30 2515724
e-mail esci@digd.azu.nl
<http://www.esci.eu.com/>

ESCI

European Society for
Clinical Investigation

**36th annual
scientific
meeting**

**10-13 April
2002**

Congress Venue :
Catholic University of Louvain
Faculty of Medicine



BRUSSELS

Local Organizer:
P. EVRARD (Belgium)
phone:
+ 32 81 42 30 21
fax:
+ 32 81 42 30 23
e mail:
docmed@mont.ucl.ac.be

Web site: <http://www.esci.eu.com>

Early registration deadline : March 1st, 2002